We previously reported the small organic N-type calcium channel blocker NP078585 that while efficacious in animal models for pain, exhibited modest L-type calcium channel selectivity and substantial off-target inhibition against the hERG potassium channel. Structure-activity studies to optimize NP078585 preclinical properties resulted in compound 16, which maintained high potency for N-type calcium channel blockade, and possessed excellent selectivity over the hERG ($120-fold) and L-type ($3600-fold) channels. Compound 16 shows significant anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain and is also efficacious in the rat formalin model of inflammatory pain.
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Calcium channels are the primary route of translating electrical signals into biochemical events that underlie key processes such as neurotransmitter release, cell excitability and gene expression. 1 Calcium channels are classified into five pharmacological and physiological subtypes: L-, N-, P/Q-, R-and T-types. Among these, the N-, P/Q-and R-type channels have all been shown to play key roles in neurotransmitter release. 2 In particular, N-type calcium channels are located at the presynaptic terminals of a subset of spinal cord neurons where they mediate transmission of pain signals from the periphery to the central nervous system. The block of N-type channels with peptide agents has been shown to play a significant role in the pathophysiological processes of inflammatory and neuropathic pain. Previously, we have reported NP078585 (Fig. 1 ) as an N-type calcium channel blocker with good in vivo efficacy in the rat formalin model of inflammatory pain following oral administration. 4 NP078585 is a potent (IC 50 = 0.11 lM) and CNS penetrant N-type channel blocker with moderate selectivity over the L-type calcium channel (IC 50 = 2.8 lM). A potential development concern is that NP078585 also blocked the hERG potassium channel (IC 50 = 0.4 lM).
In order to further optimize the development of orally available N-type blockers, a major goal was to minimize hERG channel inhibition compared to NP078585. In this regard, in the current study we assessed; (i) modification of aryl substituents on the benzyl moiety bound to the piperazine core of NP078585, (ii) conversion of amines to amides, (iii) aliphatic substitutions on the piperazine core, and (iv) replacement of the piperazine core with 3-aminomethyl-pyrrolidine (Fig. 2) . Structure-activity relationship studies initially examined a range of alternative substitution at the trimethoxybenzyl portion of NP078585 with the aim of identifying a series with improved in vitro channel selectivity profiles and with a reduction of hERG inhibition. Compounds 1-14 were prepared from intermediates A and B according to the general synthesis 5 outlined in Scheme 1.
The structure-activity studies of this chemical series were guided by a whole cell manual patch clamp electrophysiology assay for the N-type and L-type calcium channel with further assessment for hERG activity. 6 The replacement of R 1 and R 3 groups on the benzyl region of parent compound NP078585 with a t-butyl group (Table 1) , in general resulted in maintaining good N-type channel blocking affinity for most compounds. This region of the molecule appears to be fairly accommodating, accepting a t-butyl group in 3 and 5 positions being the most optimal substituents, such as compounds 3-12, all of which showed better or similar N-type affinities compared to the parent compound NP078585. The 3,5-di-t-butyl analogs (compounds 11-12) also maintained high affinity N-type inhibition with IC 50 values of 0.14-0.3 lM.
Compared to NP078585, the addition of a 4-methoxy substituent (compound 10) slightly improved affinity ($0.09 lM) and additionally dramatically improved selectivity both over the L-type channel to greater than 900-fold (IC 50 $81 lM, not shown) and the hERG channel by approximately 100-fold (IC 50 $9 lM). From this initial series, we determined that 3,5-substitution of the phenyl ring was preferred. Further, the incorporation of a hydrogen bond acceptor (-OCH 3 ) as in the case of compound 10 increased the selectivity for the N-type over the L-type and hERG targets. In general, the amine-linked analogues exhibited higher affinity for hERG as compared to the amide counterparts. Using aryl substituents (R 1 = t-butyl, R 2 = OCH 3 , R 3 = t-butyl)
and an amide-linked functional group, we further explored substitutions off the piperazine ring with aliphatic groups. Table 2 shows that S-Me substitution was tolerated off the piperazine ring adjacent to the linker (compound 15) although resulted in high affinity hERG channel blockade (IC 50 $0.9 lM). Contrastingly, S-Me substitution adjacent to the benzoyl linker (compound 16) resulted in excellent N-type channel blockade and approximately 3600-fold selectivity over the L-type channel. In addition, compound 16 maintained the favorable hERG channel block of the parent compound 10 (IC 50 = 4.9 lM). Due to its combined N-type affinity and excellent selectivity profile compound 16 was progressed into in vivo anti-nociception assessment. Further optimization of NP078585 was attempted by replacement of the piperazine core with 3-aminomethyl-pyrrolidine. We hypothesized that 3-aminomethyl-pyrrolidine could be a potential bioisostere for the piperazine core due to the relatively planar conformation of the pyrrolidine ring in combination with the flexible 3-aminomethyl group. To test this, we synthesized a series of compounds containing amine and amide groups, in combination with a 3-aminomethyl-pyrrolidine scaffold with known structural elements of NP078585 and compound 10.
Initial efforts in this study focused on analogs wherein substitutions on the aryl group were varied (Table 3 ). The synthesis of these compounds is as described in Scheme 2 and is illustrative of the general procedure. Briefly, readily available 1-benzyl-pyrrolidin-3-ylmethyl-carbamic acid tert-butyl ester was debenzylated via catalytic hydrogenation followed by coupling with 6,6-bis(4-fluorophenyl)hexanoic acid mediated by EDC and DMAP to provide the desired intermediate. Subsequent deprotection of the Boc group and reaction with the appropriate benzoic acid provided desired compounds. Reduction of the di-amide moiety with LiAlH 4 proceeded smoothly to afford di-amines compounds. 7 Compounds (17-28) generally exhibited highly favorable Ntype channel inhibition (IC 50 values $0.04-0.9 lM). Of these, compounds 18-19 and 26-27 containing bulky substituents (t-butyl) on the 3,5-position of the aryl group showed improved N-type channel inhibition compared to NP078585. Of note, compound 19 with the highest N-type affinity also showed excellent selectivity over the L-type calcium channel ($750-fold; not shown). Extending the substitution of the phenyl ring to trifluoromethyl (compounds 20-21) did not improve activity concerning N-type blockade and further, the best of these (compound 20, IC 50 $0.2 lM) exhibited a poor hERG profile. Comparing amine-linked compounds 23-27 to their amide counterparts (compounds 17-21), in general the di-amine linked analogues possessed higher affinity for both the N-type calcium channel and the hERG potassium channel as compared to their di-amide counterparts.
The stereogenic center introduced by the pyrrolidine ring appeared to have little effect on N-type calcium channel activity with the R:S IC 50 values approaching unity (Table 4 ). These observations would seem to be one of the many exceptions to Pfeiffer's rule, which states that the higher the activity of a eutomer, the higher the separation in activities between eutomer and distomer. 8 We further then focused on understanding the effect of replacing one phenyl group on the benzhydryl with piperidine (Scheme 3). The introduction of the N-piperidinyl moiety (compounds 35-37) resulted in analogs with reduced N-type affinity relative to the corresponding phenyl analogs (see Table 5 ).
Based on the encouraging results associated with compound 19, we investigated whether swapping the 'left hand' and 'right hand' side moieties attached to the 3-amino(methyl) pyrrolidine core (Table 6 ). The change proved to be well tolerated and yielded one analogue with excellent affinity for N-type calcium channel (compound 39, IC 50 $0.01 lM). Unfortunately, these modifications did not offer any advantages concerning hERG selectivity over compound 20.
Of the compounds synthesized and evaluated, compounds 10 and 16 exhibited the most promising overall in vitro target profiles; N-type blocking IC 50 s $0.04-0.09 uM and excellent selectivity over both the L-type calcium channel ($900-to 3600-fold) and hERG potassium channel ($ 100-to 122-fold). Reflective of these combined properties, compounds 10 and 16 were selected for in vivo assessment in the rat formalin model of inflammatory pain. 9 Upon intraperitoneal (ip) administration only compound 16 exhibited significant antinociceptive activity ($50-60% of vehicle-treated group) in phase II and phase IIA of the formalin response (Table 7) . Compounds 10 and 16 were also evaluated for activity in the Chung model of neuropathic pain 10 with two behavioral endpoints used: mechanical allodynia 11 and thermal hyperalgesia. 12 Animals were administered a single 30 mg/kg oral dose of each compound and were tested at 30 min intervals during a 2-3 h test period beginning 30 min after test compound administration. One-way ANOVA followed by the Bonferroni test were employed on the original raw data (not normalized) to establish the statistical significance of the differences observed with the post SNL-baseline value. Compounds 10 and 16 both demonstrated efficacious inhibition of nerve ligation-induced thermal hyperalgesia (ranging from $54% to 86% maximal antinociception; Table 8 ). Contrastingly, only compound 16 exhibited discernible antiallodynic effects in vivo. This may reflect distinct underlying pathophysiological mechanisms contributing to these two pain behavioral endpoints together with any as yet-to-be determined unique state-dependent target and/or off-target activities related to compounds 10 and 16.
In summary, we have described a series of piperazine and 3-amino(methyl)pyrrrolidine analogues, some of which display both excellent potency as N-type calcium channel antagonists and possess favorable selectivity over the hERG potassium channel. Among these, compound 16 exhibited good selectivity over the L-type calcium channel and showed analgesic activity in both inflammatory and neuropathic rat pain models. The development of N-type calcium channel blockers for eventual clinical usage will require optimization of multiple parameters, including high affinity and selectivity for the N-type target, suitable pharmacokinetic charac- Compounds, prepared in propylene glycol, were administered at a dose of 30 mg/kg ip at 3 mL/kg 30 min prior to intraplantar injection of formalin into the hindpaw. Data are the mean percent of vehicle effect (MPE) ± SEM, n = 5 animals tested for compound 10 and n = 6 animals for compound 16. Data were analyzed for significance using a one-way ANOVA to vehicle-treated group. ⁄⁄ P <0.01; ⁄⁄⁄ P <0.001 teristics incorporating oral bioavailability and blood-brain barrier penetration, and a wide therapeutic index against the cardiovascular, nervous and other systems. Similar to our previous reports, 4, 13 only a subset of high affinity in vitro N-type channel blockers in the current study exhibited efficacy in rodent neuropathic and inflammatory pain models. An exact correlation between in vitro target affinity and in vivo analgesia is generally lacking across many similar studies, making direct compound-based predictive assessments difficult and requiring empirical elucidation of efficacy. In part, this may reflect a requirement for an optimal combination of high affinity N-type channel blockade acting via a state-and/ or frequency-dependence mechanism and reflective of the underlying pathophysiology associated with specific pain states.
14 Compounds were also assayed against the hERG potassium channel stably expressed in HEK293 cells. Whole cell barium currents were elicited from a holding potential of À100 mV to the peak of current-voltage relation for each channel type. With a few exceptions, each compound was examined for blockade on 3-5 cells. Testing compounds for blockade of N-type and L-type calcium channels was performed by whole-cell manual patch clamp analysis using a near half-maximal concentration of compound applied to HEK293 cells as per Ref. 4 . Pipettes (in the range of 2-4 MX) were filled with an internal solution containing 108 mM Cs-methanesulfonate, 4 mM MgCl 2 , 9 mM EGTA, 9 mM HEPES (pH 7.2 adjusted with TEA-OH) for N-and L-type channel currents and 130 KCl, 1 MgCl 2 , 5 EGTA, 10 HEPES, 5 K 2 ATP (pH 7.2 with KOH) for hERG K + channel currents. Whole-cell barium currents were recorded using an Axopatch 200B amplifier and an extracellular recording solution comprised of 5 mM BaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 40 mM TEA-Cl, 10 mM glucose, 97.5 mM CsCl (pH 7.2 adjusted with TEA-OH) for N-and L-type channel currents and 137 NaCl, 4 KCl, 1.8 CaCl, 1 MgCl 2 , 10 HEPES, 10 glucose (pH 7.4 with NaOH) for hERG K + channel currents. Data were filtered at 1 kHz using a four pole Bessel filter and digitized at a sampling frequency of 2 kHz. Wholecell barium current inhibition was measured from a holding potential of À80 mV to a test potential of +10 mV, applied at 0.2 Hz, or from a holding potential of À80 mV to +1-mV following a 1 s prepulse to À60 mV, applied at 0.067 Hz for N-type channels. L-type channel currents were obtained from a holding potential of À80 mV to a test potential of +10 mV, applied at 0.2 Hz. To study compound effects on the hERG channel using manual patch clamp, the peak of the slowly deactivating tail current was examined. A 2 s depolarization to +60 mV from a holding potential of À80 mV, followed by a repolarization to À50 mV was used to generate the hERG tail currents. The estimated IC 50 value was then calculated for all compounds tested in the various electrophysiological assays such that estimated IC 50 = [D]/((1/fr)-1) where [D] is the drug concentration, and fr is the fraction of current remaining after drug application. This analysis assumes that there is a 1:1 interaction between the drug and the channel. The term 'estimated IC 50 value' is utilized since the determination of IC 50 value via a single concentration point may be slightly less precise than fits to entire concentration-dependent response curves. For some compounds IC 50 values were obtained using data obtained from multiple concentrations and fitted with a logistic function where max is the maximum current amplitude in the absence of compound, min is the minimum current amplitude at steady-state inhibition with the compound and n H is the Hill slope: Compounds, prepared in propylene glycol, were administered at a dose of 30 mg/kg po at 1 mL/kg after baseline assessment for neuropathic pain and behavioral assessments were performed at 30 min intervals post-administration, up to 3 h. Data are the mean percent of maximal possible antinociception ± SEM; n = 5-6 animals. The following formula was used to calculate the % anti-allodynic activity: 100% Â [(paw withdrawal thresholds after drug treatment À postSNL baseline paw withdrawal thresholds)/ (preSNL baseline paw withdrawal thresholds À postSNL baseline paw withdrawal thresholds). The following formula was used to calculate the % anti-hyperalgesic activity: 100% Â [(paw withdrawal latencies after drug treatment À postSNL baseline paw withdrawal latencies)/(preSNL baseline paw withdrawal latencies À postSNL baseline paw withdrawal latencies). Data from the ipsilateral paw were also assessed by a one-way ANOVA-post-hoc for statistical significance. ⁄⁄ P <0.01.
